Measuring cytomegalovirus (CMV) immunity to direct optimal length of CMV prophylaxis following lung transplantation.

Not Applicable

Completed

• Conditions: ung Transplantation; Cytomegalovirus; Lung Transplantation; Respiratory - Other respiratory disorders / diseases; Infection - Other infectious diseases

• Registration Number: ACTRN12612000551897
• Lead Sponsor: Dr Glenn Westall, for The Alfred Hospital

Brief Summary

sing the QFN-CMV blood test to dictate the length of antiviral medication cover was shown to reduce the incidence of CMV infection within the transplanted lung.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-05-24
• Study Completion: 2017-04-30
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 119

Inclusion Criteria

Adult (greater than or equal to 18yrs) lung transplant recipients, who are at risk of CMV reactivation, and who have provided written informed consent.

Exclusion Criteria

(1) CMV seronegative recipient and seronegative donor, (2) known ganciclovir resistance, (3) valganciclovir-related neutropenia, (4) BOS grad 3 or BOS with unstable FEV1, (5) hospitalized requiring intubation or mechanical ventilation, (6) active treatment for acute graft rejection, (7) pregnant, lactating, or breast feeding, (8) known hypersensitivity to valganciclovir, or (9) any other condition in the investigators medical opinion that precludes the patients participation.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The effectiveness of QuantiFERON-CMV directed antiviral prophylaxis on the incidence of CMV reactivation within the lung allograft in patients at-risk of CMV reactivation. CMV reactivation within the lung allograft will be assessed as the presence of CMV in the BAL, deifined as greater than or equal to 600 copies.[Within 18 months of transplant]